Research programme: Tie-1 targeted antibodies - Shire

Drug Profile

Research programme: Tie-1 targeted antibodies - Shire

Alternative Names: Angiogensis inhibitors - Shire; DX-2240

Latest Information Update: 29 Jan 2016

Price : $50

At a glance

  • Originator Dyax
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Jan 2016 Dyax has been acquired by and merged into Shire
  • 12 Feb 2008 DX 2240 licensed to sanofi-aventis worldwide
  • 22 Jan 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top